– USA, UT – BlueWind Medical, Ltd., a medical device company working to transform neuromodulation therapy for overactive bladder, today announced the appointment of Dr. Liz Kwo, (M.D., MPH) to its Board of Directors.
“Dr. Kwo is a distinguished physician, leader, and entrepreneur with extensive knowledge in building and scaling healthcare products to improve outcomes and quality care. We are honored to have her join our board of directors and look forward to working together as we advance our efforts to bring safe and effective solutions to people suffering from overactive bladder,” said Chairman and CEO, Dan Lemaitre.
About Dr. Liz Kwo
As a practicing physician and experienced entrepreneur, Dr. Kwo has focused her career on leveraging innovative technology to enhance the patient experience and improve population health. She brings deep expertise in data science, automation, and artificial intelligence, with a unique background in applying digital health to care delivery models.
“I have focused my career on transforming healthcare and I am especially passionate about therapies with the potential to redefine current standards of care and improve the quality of life for patients,” said Dr. Kwo. “I am pleased to join BlueWind Medical at this exciting phase and support the company’s mission to revolutionize neuromodulation therapy for overactive bladder.”
Before joining Everly Health, Dr. Kwo was the deputy Chief Clinical Officer for Anthem, now Elevance Health, where she focused on pioneering care management and utilization delivery for nearly 43 million Americans. She is currently a faculty lecturer at Harvard Medical School and a practicing physician in urgent and occupational medicine at Cambridge Health Alliance, a teaching affiliate of Harvard Medical School. Leaning on her entrepreneurial roots, Dr. Kwo is also an active angel investor in the healthcare community with an interest in technology-enabled healthcare delivery.
About BlueWind Medical Ltd.
BlueWind Medical is an innovative medical device company that is transforming neuromodulation therapy for the treatment of an Overactive Bladder. BlueWind Medical has developed a miniature tibial neuromodulation solution for OAB that is implanted near the ankle in a minimally invasive outpatient procedure under local anesthesia. The patient-centric system allows for therapy customization to enhance patient response and includes a lightweight wearable device that fits around the ankle. The OASIS study is being conducted under an Investigational Device Exemption from the FDA and completed enrollment in November 2021. RENOVA iStim is not approved for use in the U.S.
For more information: https://bluewindmedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
